Openbookopenbook
Equity
Swedish Orphan Biovitrum AB (publ)(SWOBY)
USD --+0.00%
Reward65Moderate
Risk24Low
📊75%Data
Thin 2% profit margin
SWOBY
+0.0 · +0.00%
USD · PINK
Swedish Orphan Biovitrum AB (publ) | Healthcare
Quality Compounder
Market Cap:15.15Bn
ℹ️
Reward Rating
65
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
24
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SWOBY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: kr27.00.

What is Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SWOBY · Verdict

Solid reward · low risk

SWOBY scores well on volatility and valuation with no major weaknesses flagged in the model.

Based on 88% data coverage

SWOBY · Verdict

What’s working & what to watch

Strengths 5

  • Volatility95/100

    Top decile vs peers

  • Valuation84/100

    P/E 24.6× · PEG 0.35

  • Cash flow75/100

    19% free-cash-flow margin

  • Growth68/100

    Rev +14.5% CAGR · earnings -43.4%

  • Profitability65/100

    2% net margin · 1% ROE

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 15.15B, and a P/E ratio of 268.9x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (65)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap15.15B
P/E Ratio268.9375
Dividend YieldN/A
52 Week High23.59
52 Week Low13.1
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding691M
No. of Employees1,888
IndustryDrug Manufacturers - Specialty & Generic
ExchangePINK
Beta0.176
CurrencyUSD · Reports in SEK
Websitewww.sobi.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.